NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3077% above fair value

$12.02−0.50 (-3.99%)

Close on Nov 12, 2026Market cap $412.58MP/E –Yield 0.00%

NeuroPace operating margin

Operating margin is operating income as a percentage of revenue.

NeuroPace's operating margin for the twelve months ending Sep 30, 2026 was -9.5%. For fiscal 2025 it was -16.3%, against -27.1% the year before. The highest annual figure on record is -16.3% in fiscal 2025.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-16.3%	+10.8
FY2024	Dec 31, 2024	-27.1%	+14.4
FY2023	Dec 31, 2023	-41.5%	+48.1
FY2022	Dec 31, 2022	-89.6%	−37.1
FY2021	Dec 31, 2021	-52.5%	−20.8
FY2020	Dec 31, 2020	-31.7%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-9.0%	+8.2
Q2 FY2026	Jun 30, 2026	-22.5%	+19.5
Q1 FY2026	Mar 31, 2026	-25.2%	−2.4
Q4 FY2025	Dec 31, 2025	6.8%	+23.8
Q3 FY2025	Sep 30, 2025	-17.2%	+2.9
Q2 FY2025	Jun 30, 2025	-42.0%	−9.6
Q1 FY2025	Mar 31, 2025	-22.9%	+18.8
Q4 FY2024	Dec 31, 2024	-17.0%	+11.0
Q3 FY2024	Sep 30, 2024	-20.1%	+16.1
Q2 FY2024	Jun 30, 2024	-32.4%	+15.2
Q1 FY2024	Mar 31, 2024	-41.6%	+15.9
Q4 FY2023	Dec 31, 2023	-28.0%	+49.0
Q3 FY2023	Sep 30, 2023	-36.2%	+55.2
Q2 FY2023	Jun 30, 2023	-47.6%	+60.0
Q1 FY2023	Mar 31, 2023	-57.5%	+28.3
Q4 FY2022	Dec 31, 2022	-77.1%	+4.9
Q3 FY2022	Sep 30, 2022	-91.4%	−31.0
Q2 FY2022	Jun 30, 2022	-107.6%	−71.1
Q1 FY2022	Mar 31, 2022	-85.8%	−51.3
Q4 FY2021	Dec 31, 2021	-82.0%	−54.3
Q3 FY2021	Sep 30, 2021	-60.4%	−51.3
Q2 FY2021	Jun 30, 2021	-36.5%	+8.6
Q1 FY2021	Mar 31, 2021	-34.5%	+20.2
Q4 FY2020	Dec 31, 2020	-27.7%	–
Q3 FY2020	Sep 30, 2020	-9.1%	–
Q2 FY2020	Jun 30, 2020	-45.1%	–
Q1 FY2020	Mar 31, 2020	-54.7%	–